Company intelligence / Profile preview

YD Biopharma

Ownership: Private
Development stage: Other

Overview

YD Biopharma (also known as YD Group) is a biotech company focused on developing advanced exosome-based therapies for ophthalmic diseases and innovative methylation-based diagnostics for early cancer detection, particularly pancreatic and breast cancers. The company operates proprietary platforms for both therapeutic and diagnostic areas, with programs ranging from pre-clinical to commercial/late-stage validation. YD Biopharma is currently undergoing a merger to become publicly listed on Nasdaq.

Therapeutic areas: OncologyOphthalmology
Modalities: Exosome-based therapyStem cell therapySmall molecule drugsDiagnostic technology/platforms
Industry: Biotech

Partnerships

Novartis – clinical trial drug supply partnership since 20153D Global Biotech Inc. – exclusive licensing/collaboration on corneal MSC/exosomesEG BioMed Taiwan – licensing/collaboration on DNA methylation diagnostic platforms for pancreatic/breast cancers

Beyond the preview

Go deeper on YD Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YD Biopharma.

Explore the full profile